William Blair analyst Max Smock has maintained their neutral stance on CRL stock, giving a Hold rating on April 21.
Max Smock has given his Hold rating due to a combination of factors that reflect both positive and cautious elements in Charles River Labs’ recent performance and outlook. The company reported better-than-expected first-quarter results, with revenues and adjusted earnings surpassing estimates, driven by strong performances in their DSA and RMS segments. Additionally, the company improved its 2025 outlook, suggesting a less severe decline in organic revenue and a higher range for adjusted EPS than previously anticipated.
Despite these positive developments, Max Smock remains cautious due to broader market uncertainties. The encouraging signs of demand stabilization, such as improved DSA booking activity, are offset by concerns over U.S. government funding cuts, a slower-than-expected start to biotech funding, and potential biopharma tariffs. These factors contribute to a mixed outlook, leading to the Hold rating as the company navigates these challenges while showing signs of operational strength.
In another report released on April 21, Jefferies also maintained a Hold rating on the stock with a $100.00 price target.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRL in relation to earlier this year.